Marinus Pharmaceuticals Inc (NASDAQ:MRNS) shares were down 5.1% during trading on Wednesday . The stock traded as low as $5.85 and last traded at $6.14. Approximately 776,205 shares were traded during trading, a decline of 9% from the average daily volume of 855,307 shares. The stock had previously closed at $6.47.
Several research analysts have recently commented on MRNS shares. BidaskClub raised Marinus Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Thursday, September 20th. Cantor Fitzgerald set a $19.00 price objective on Marinus Pharmaceuticals and gave the stock a “buy” rating in a report on Tuesday, September 25th. ValuEngine lowered Marinus Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Saturday, October 6th. Zacks Investment Research raised Marinus Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Wednesday, October 10th. Finally, Mizuho reissued a “buy” rating and set a $13.00 price objective on shares of Marinus Pharmaceuticals in a report on Thursday, August 2nd. Two equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. Marinus Pharmaceuticals presently has a consensus rating of “Buy” and a consensus target price of $19.67.
The company has a market capitalization of $405.25 million, a PE ratio of -7.69 and a beta of 2.53.
Institutional investors and hedge funds have recently modified their holdings of the business. Trexquant Investment LP purchased a new stake in Marinus Pharmaceuticals in the second quarter worth approximately $102,000. GSA Capital Partners LLP purchased a new stake in Marinus Pharmaceuticals in the second quarter worth approximately $141,000. Barclays PLC purchased a new stake in Marinus Pharmaceuticals in the first quarter worth approximately $232,000. Rhumbline Advisers purchased a new stake in Marinus Pharmaceuticals in the second quarter worth approximately $245,000. Finally, Dynamic Technology Lab Private Ltd purchased a new stake in Marinus Pharmaceuticals in the second quarter worth approximately $363,000. 63.64% of the stock is owned by institutional investors and hedge funds.
About Marinus Pharmaceuticals (NASDAQ:MRNS)
Marinus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on developing and commercializing therapeutics to treat epilepsy and neuropsychiatric disorders. Its clinical stage product candidate, ganaxolone, is an allosteric modulator of GABAA, developed in three different dose forms: intravenous (IV), capsule, and liquid.
Read More: Do closed-end mutual funds pay dividends?
Receive News & Ratings for Marinus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Marinus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.